Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers.
Kawana K, Yasugi T, Kanda T, Kino N, Oda K, Okada S, Kawana Y, Nei T, Takada T, Toyoshima S, Tsuchiya A, Kondo K, Yoshikawa H, Tsutsumi O, Taketani Y.
Kawana K, et al. Among authors: takada t.
Vaccine. 2003 Oct 1;21(27-30):4256-60. doi: 10.1016/s0264-410x(03)00454-7.
Vaccine. 2003.
PMID: 14505907
Clinical Trial.